Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregional Esophageal Cancer.
- Author:
Gyeong Won LEE
1
;
Jung Hun KANG
;
Hun Gu KIM
;
In Gyu HWANG
;
Ki Shik SHIM
;
Seok Hyun KIM
;
Won Sep LEE
;
Woon Tae JUNG
;
Ok Jae LEE
;
Jung Hyeun CHO
;
Joung Soon JANG
;
Kyu Yong CHAE
;
Jong Seok LEE
Author Information
1. Department of Internal Medicine, College of Medicine, Gyeong-Sang National University, Jinju, Korea. Jonglee@nongae. gsnu.ac.kr
- Publication Type:Original Article
- Keywords:
Esophageal neoplasm;
Induction chemotherapy;
Concurrent chemoradiotherapy
- MeSH:
Brachytherapy;
Chemoradiotherapy*;
Cisplatin;
Deglutition Disorders;
Drug Therapy;
Esophageal Neoplasms*;
Fluorouracil;
Follow-Up Studies;
Humans;
Induction Chemotherapy*;
Mucositis;
Survival Rate
- From:Cancer Research and Treatment
2001;33(6):489-494
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The object of this study is to evaluate the efficacy and toxicity of induction chemotherapy followed by concomitant chemoradiotherapy in locoregional esophageal cancer. MATERIALS AND METHODS: Between December 1992 and December 1999, 43 patients with locoregional esophageal cancer were enrolled in this phase II trial. Patients were treated with 2-cycles of induction chemotherapy followed by concomitant chemoradiotherapy. F-P chemotherapy consists of 1,000 mg/m2/Day of 5-FU as continuous infusion on day 1~5 and 80 mg/m2 of cisplatin as an intravenous bolus on day 1 and was repeated every 3~4 weeks. All patients received 60 Gy of external beam radiation concomitantly with F-P chemotherapy; intraluminal brachytherapy was added in 12 patients. A total of 4 cycles of chemotherapy were delivered. No further treatment was planned in patients who achieved complete remission after completion of the treatment. RESULTS: Among the 43 patients entered, 35 patients completed the protocol. Of the 35 evaluable patients, 12 patients (34%) achieved complete response and 13 patients (37%) achieved partial response. In 26 of 33 patients, dysphagia was improved. At a median follow-up of 22 months, the 2-year and 5-year survival rates were 39% and 19%, respectively. The median survival duration of the complete responder group was 69 months (4~100 months) and the 2-year survival rate of the complete responder group was 82%. Toxicities were tolerable, comprised of mucositis and cytopenia. CONCLUSION: Induction chemotherapy followed by concurrent chemoradiotherapy in locoregional esophageal cancer is well tolerated and effective.
